By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Myriad Genetics, Inc. 

320 Wakara Way

Salt Lake City  Utah  84108  U.S.A.
Phone: 801-584-3600 Fax: 801-584-3640


SEARCH JOBS

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.

YEAR FOUNDED:

May 1991

LEADERSHIP:

CEO and Founder: Mark Capone

CMO (Medical): Richard Wenstrup

CFO: Bryan Riggsbee

CSO (Scientific): Jerry Lanchbury

JOBS:

Please click here for Myriad Genetics job opportunities.

CLINICAL TRIAL

Please click here for clinical trial information.


PRODUCTS:

All Products

FOLLOW MYRIAD GENETICS:



Key Statistics


Email: info@myriad.com
Ownership: Public

Web Site: Myriad Genetics
Employees:
Symbol: MYGN
 









Company News
Myriad Genetics (MYGN) Completes Acquisition Of Assurex Health 9/2/2016 7:28:18 AM
Apples to Apples: Comparing EXACT Sciences (EXAS) to Myriad Genetics (MYGN) 8/15/2016 8:56:03 AM
Myriad Genetics (MYGN) Reports Fiscal Fourth-Quarter 2016 Financial Results 8/10/2016 8:03:23 AM
Myriad Genetics (MYGN) Pays $225 Milllion for Fast-Growing Startup Assurex Health 8/4/2016 6:09:23 AM
Myriad Genetics (MYGN) To Announce Fiscal Fourth-Quarter 2016 Financial Results On August 9 7/27/2016 8:10:47 AM
Myriad Genetics (MYGN)’s myChoice HRD Test Successfully Identifies Patients That Meet Primary Endpoint In Tesaro (TSRO)’s Pivotal Phase 3 Ovarian Cancer Study With Niraparib 6/29/2016 6:58:24 AM
Myriad Genetics (MYGN) Board Approves $200 Million Increase In Share Repurchase Program 6/7/2016 1:52:16 PM
ASCO2016: Myriad Genetics (MYGN) Will Present Three New Hereditary Cancer Studies At The ASCO Annual Meeting 6/6/2016 3:45:40 PM
ASCO2016: Myriad Genetics (MYGN) myRisk Hereditary Cancer Test Demonstrates The Magnitude Of Breast And Ovarian Cancer Risk In Nearly 100,000 Patients 6/6/2016 3:01:28 PM
Myriad Genetics (MYGN) Snaps Up Sividon Diagnostics in $56 Million Deal 6/1/2016 8:05:11 AM
12345678910...
//-->